BeOne Medicines Ltd. (ONC)
ONC Stock Price Chart
Explore BeOne Medicines Ltd. interactive price chart. Choose custom timeframes to analyze ONC price movements and trends.
ONC Company Profile
Discover essential business fundamentals and corporate details for BeOne Medicines Ltd. (ONC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
2 Feb 2016
Employees
11.00K
Website
https://beonemedicines.comCEO
John V. Oyler
Description
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.
ONC Financial Timeline
Browse a chronological timeline of BeOne Medicines Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Nov 2025
EPS estimate is $0.31.
Earnings released on 6 Aug 2025
EPS came in at $0.84 surpassing the estimated $0.48 by +75.00%, while revenue for the quarter reached $1.32B , missing expectations by -3.36%.
Earnings released on 7 May 2025
EPS came in at $1.22 surpassing the estimated -$0.71 by +271.83%, while revenue for the quarter reached $1.12B , missing expectations by -10.36%.
Earnings released on 27 Feb 2025
EPS came in at -$1.43 falling short of the estimated -$0.88 by -62.50%, while revenue for the quarter reached $1.13B , beating expectations by +8.53%.
Earnings released on 12 Nov 2024
EPS came in at -$1.15 falling short of the estimated -$0.88 by -30.68%, while revenue for the quarter reached $1.00B .
Earnings released on 7 Aug 2024
EPS came in at -$1.15 surpassing the estimated -$2.10 by +45.24%, while revenue for the quarter reached $751.65M .
Earnings released on 30 Jun 2024
EPS came in at -$0.09 , while revenue for the quarter reached $929.17M .
Earnings released on 31 Dec 2023
EPS came in at -$1.96 , while revenue for the quarter reached $634.41M .
Earnings released on 30 Sept 2023
EPS came in at $0.15 , while revenue for the quarter reached $781.31M .
Earnings released on 30 Jun 2023
EPS came in at -$0.28 , while revenue for the quarter reached $595.26M .
Earnings released on 31 Mar 2023
EPS came in at -$0.26 , while revenue for the quarter reached $447.80M .
Earnings released on 31 Dec 2022
EPS came in at -$2.35 , while revenue for the quarter reached $380.10M .
Earnings released on 30 Sept 2022
EPS came in at -$0.41 , while revenue for the quarter reached $387.63M .
Earnings released on 30 Jun 2022
EPS came in at -$0.43 , while revenue for the quarter reached $341.57M .
Earnings released on 31 Mar 2022
EPS came in at -$0.33 , while revenue for the quarter reached $306.63M .
Earnings released on 31 Dec 2021
EPS came in at -$0.47 , while revenue for the quarter reached $213.98M .
Earnings released on 30 Sept 2021
EPS came in at -$0.34 , while revenue for the quarter reached $206.44M .
Earnings released on 30 Jun 2021
EPS came in at -$0.40 , while revenue for the quarter reached $149.99M .
Earnings released on 31 Mar 2021
EPS came in at $0.05 , while revenue for the quarter reached $605.87M .
Earnings released on 31 Dec 2020
EPS came in at -$0.40 , while revenue for the quarter reached $100.10M .
Earnings released on 30 Sept 2020
EPS came in at -$0.37 , while revenue for the quarter reached $91.08M .
ONC Stock Performance
Access detailed ONC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.